Market Overview - The Shanghai Composite Index is at 3832.05 points, above the six-month moving average, with a slight increase of 0.10% [1] - The total trading volume of A-shares today is 940.447 billion yuan [1] Stocks Performance - A total of 117 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Kaiwang Technology (9.08%) - Liwang Co., Ltd. (6.87%) - Shenghui Technology (6.51%) [1] - Other stocks that have just crossed the six-month moving average with smaller deviation rates include: - China Merchants Securities - Renxin New Materials - Jihigh Development [1] Detailed Stock Data - The top three stocks with the highest daily increase and their respective metrics are: - Kaiwang Technology: 9.71% increase, 7.19% turnover rate, latest price 38.42 yuan [1] - Liwang Co., Ltd.: 13.11% increase, 12.32% turnover rate, latest price 30.03 yuan [1] - Shenghui Technology: 9.64% increase, 9.67% turnover rate, latest price 7.51 yuan [1] - Additional stocks with notable performance include: - Yuejian Intelligent: 5.39% increase, 1.95% turnover rate, latest price 16.03 yuan [1] - Haixing Electric: 4.15% increase, 1.24% turnover rate, latest price 28.13 yuan [1] Additional Stocks with Minor Deviations - Stocks with minor deviations include: - Lingge Technology: 2.11% deviation [2] - Lixin Energy: 1.98% deviation [2] - Fengshan Group: 1.95% deviation [2]

Core Viewpoint - Yipinhong (300723) has received approval from the National Medical Products Administration for its oral solution of L-carnitine, indicating a significant step in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Approvals - Yipinhong's subsidiary has obtained a drug registration certificate for L-carnitine oral solution, which is indicated for primary systemic carnitine deficiency and related symptoms [1] - The approved L-carnitine oral solution is classified as a Category B product under the national medical insurance, with an estimated sales scale of approximately 1.257 billion yuan in 2024 [1] - In addition to L-carnitine, Yipinhong has received approvals for several other drugs, including escitalopram oxalate drops (estimated sales of 1.88 billion yuan in 2024) and clindamycin palmitate ester granules (estimated sales of 100 million yuan in 2024) [2][2] - The company has also received approval for oseltamivir phosphate capsules, which are used for the treatment and prevention of influenza in adults and children [2] Group 2: Innovative Drug Development - Yipinhong has disclosed that its innovative drug APH03621, a GnRH receptor antagonist for endometriosis treatment, has received clinical trial registration acceptance [3] - The company is advancing its gout drug AR882, with global Phase III clinical trials expected to complete enrollment by August 2025, and data from these trials anticipated in 2026 [3]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its product, L-Carnitine Oral Solution, which is indicated for the treatment of primary systemic carnitine deficiency [1] Group 1 - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for L-Carnitine Oral Solution [1] - The indication for L-Carnitine Oral Solution is specifically for treating primary systemic carnitine deficiency [1]

Core Viewpoint - The company has received approval for the registration of L-Carnitine oral solution, which is indicated for the treatment of primary systemic carnitine deficiency [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration [1] - The approved product, L-Carnitine oral solution, addresses a specific medical condition, enhancing the company's product portfolio [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its oral solution of L-carnitine, which is indicated for the treatment of primary systemic carnitine deficiency and related conditions [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for L-carnitine oral solution [1] - The approved indication includes treatment for primary systemic carnitine deficiency, which can manifest as recurrent Reye-like syndrome, hypoketotic hypoglycemia, and/or cardiomyopathy [1] - The product is also indicated for short-term and long-term treatment of secondary carnitine deficiency due to congenital metabolic disorders, with recommended dosages for infants and children [1] Industry Summary - L-carnitine is a naturally occurring substance essential for energy metabolism in mammals, primarily facilitating lipid metabolism [1] - The supplement can alleviate metabolic disorders caused by deficiencies, improving the function of skeletal muscle and cardiac tissues [1]

Core Viewpoint - Yipinhong (300723) announced the approval of its oral solution of L-carnitine by the National Medical Products Administration, which is intended for the treatment of primary systemic carnitine deficiency and secondary carnitine deficiency due to congenital metabolic disorders [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., received the drug registration certificate for L-carnitine oral solution [1] - The approved drug is indicated for both short-term and long-term treatment of specific carnitine deficiencies [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of L-Carnitine oral solution, which is indicated for treating primary systemic carnitine deficiency and related conditions [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for L-Carnitine oral solution [1] - The approved indication for L-Carnitine oral solution includes treatment for primary systemic carnitine deficiency, which can manifest as recurrent Reye-like syndrome, hypoketotic hypoglycemia, and/or cardiomyopathy [1] - The product is also indicated for short-term and long-term treatment of secondary carnitine deficiency due to congenital metabolic disorders, with recommended dosages for infants and children included in the instructions [1] Group 2: Product Functionality - L-Carnitine is a naturally occurring substance essential for energy metabolism in mammals, primarily facilitating lipid metabolism [1] - The main functions of L-Carnitine include transporting long-chain fatty acids into the mitochondrial matrix for oxidation and providing energy to cells, as well as exporting short-chain acyl groups produced within the mitochondria [1] - Supplementation of L-Carnitine can alleviate metabolic disorders caused by its deficiency, improving the functionality of skeletal muscle and cardiac tissues [1]

证券代码：300723 证券简称：一品红 公告编号：2025-063 一品红药业集团股份有限公司 关于全资子公司获得左卡尼汀口服溶液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于左卡尼汀口服溶 液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：左卡尼汀口服溶液 英文名/拉丁名：Levocarnitine Oral Solution 主要成份：左卡尼汀 注册分类：化学药品 4 类 规 格：10ml:1g 药品注册标准编号：YBH23652025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格： 6 支/盒 处方药/非处方药：处方药 剂 型：口服溶液剂 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售 ...

Core Viewpoint - The approval of the drug registration certificate for L-carnitine oral solution marks a significant milestone for the company, enhancing its product pipeline and competitiveness in the chronic disease medication sector [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for L-carnitine oral solution [1] - The L-carnitine oral solution is indicated for the treatment of primary systemic carnitine deficiency [1] - The expected sales scale for this product in public hospitals in urban and county-level areas in China is approximately 1.257 billion RMB in 2024 [1] Group 2: Market Impact - The registration certificate enables the company to sell this specific drug in the domestic market, which is anticipated to positively impact sales [1] - The introduction of this product will further enrich the company's product categories, strengthening its position in the chronic disease medication market [1]

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. The company was listed on November 16, 2017. Its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1][2]. Financial Performance - As of August 31, Yipinhong reported a revenue of 584 million yuan for the first half of 2025, a year-on-year decrease of 36.02%. The net profit attributable to shareholders was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has cumulatively distributed 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yipinhong's stock price decreased by 2.00%, trading at 58.30 yuan per share, with a total market capitalization of 26.334 billion yuan. The stock has increased by 241.74% year-to-date but has seen a decline of 4.06% in the last five trading days and 11.84% in the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a stock trading list) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period. The average circulating shares per person decreased by 0.49% to 19,553 shares [2]. - As of June 30, 2025, the eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]. Industry Classification - Yipinhong belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with concepts including anti-influenza, pharmaceutical e-commerce, hepatitis treatment, monkeypox concept, and traditional Chinese medicine [2].